RSR Explains Targeted Antibodies

The mainstream media should be running weekly headlines
updating the public on the latest progress with targeted antibody treatment.
For some reason though, for now, if you want to keep up with the latest astounding
cancer treatment developments, you'll have to keep tuning in to BEL and Real Science Radio!
For that see rsr.org/targeted-antibodies.

Today's program, with Jonathan Bartlett, provides an insight
into how the immune system targets germs.   

* Programmed "Mutations" or "Permutations" of Antibodies: Real Science Radio host Bob Enyart turns to RSR's targeted-antibody expert, Jonathan Bartlett, who explains both the molecular biology behind this new treatment and the worldview implications ahead of it. Bartlett also discusses the impossibility that an evolutionist faces in trying to understand such a treatment and why so many scholars are fleeing Darwinism.
 
* Hear Also
: You may want to hear Jonathan's 2012 RSR interview and then visit the Blyth Institute at blythinstitute.org, and you can check out the Alternatives to Methodological Naturalism Conference at am-nat.org


* May 2016 Update: This time it's lung cancer! According to Britain's Daily Express, "Merchant seaman Simon Lamont-Brown, 50, was bedridden in a hospice and near death from lung cancer before he was given the breakthrough treatment. He said it was like a Lazarus effect "because I just rose from the dead". The drug has few side effects because it harnesses the body's own immune system to fight tumours. Nivolumab has had "remarkable" success fighting end-stage lung cancer in trials, experts say. It is also effective against other cancers." See more about this and all the latest developments at rsr.org/targeted-antibodies.